{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-001774","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.443291+00:00","generated_at":"2026-06-26T23:59:21.373848+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Corvus reports Q4 net loss of $9.2M, cash $69.5M; plans Phase 2 trials in NSCLC and RCC","bullets":["Net loss Q4 2021 $9.2M vs net income $27.3M in Q4 2020 (incl $37.5M deconsolidation gain).","Full year 2021 net loss $43.2M vs $6.0M in 2020; R&D expenses $29.1M down from $31.8M.","Cash, equivalents and securities $69.5M at Dec 31, 2021, up from $44.3M; FY2022 cash burn guidance $34-36M.","Plans randomized Phase 2 trial of mupadolimab plus chemo in front-line NSCLC (150 patients).","Plans Phase 2 trial of ciforadenant plus ipilimumab/nivolumab in front-line RCC with Kidney Cancer Consortium."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-001774","json":"https://secwatch.observer/filing/0001171843-22-001774.json","markdown":"https://secwatch.observer/filing/0001171843-22-001774.md","text":"https://secwatch.observer/filing/0001171843-22-001774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184322001774/0001171843-22-001774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184322001774/f8k_031022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:59:21.373848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}